MergerLinks - Stefano Beschi

Sort

target

Amdipharm Mercury

bidder

Advanz Pharma Corp

£2,300m

dealmakers

United KingdomUnited Kingdom

Pharmaceuticals

Private

target

Actavis (uk And Ireland)

bidder

Intas Pharmaceuticals

£603m

dealmakers

Czechia

Pharmaceuticals

PrivateDisposalPrivate Equity

target

Zentiva Group As

bidder

Advent International Corporation

£1,643m

dealmakers

AustraliaAustralia

Pharmaceuticals

PrivateMerger

target

Arrow Pharmaceuticals

bidder

Apotex

value n/a

dealmakers

Netherlands

Pharmaceuticals

PrivateDisposal

target

Apotex Europe Holding

bidder

Aurobindo Pharma

value n/a

dealmakers

Singapore

Pharmaceuticals

PrivateDisposalPrivate Equity

target

Dsm Sinochem Pharmaceuticals Pte

bidder

Bain Capital

£443m

dealmakers

ItalyItaly

Pharmaceuticals

PublicAcquisitionTender OfferPrivate EquityMajorityCross Border

target

Recordati

bidder

Cvc Capital Partners

£2,884m

dealmakers

Spain

Specialty Chemicals

AcquisitionPrivatePrivate EquityPrivate Equity

target

Euromed

bidder

Dermapharm Holding

value n/a

dealmakers

Italy

Pharmaceuticals

AcquisitionPrivateMajorityPrivate Equity

target

Neopharmed Gentili

bidder

ARDIAN

value n/a

dealmakers

Czechia

Pharmaceuticals

PrivateAcquisitionPrivate EquityMajorityCross Border

target

WALMARK

bidder

Cinven

value n/a

dealmakers

Germany

Pharmaceuticals

AcquisitionPrivate EquityMajorityPrivateDisposalCross Border

target

Pharmazell Group

bidder

Bridgepoint Group

value n/a

dealmakers

Belgium

Health Care Services

AcquisitionPrivateMajorityPrivate EquityCross Border

target

Vision Healthcare

bidder

Avista Healthcare Partners

£273m

dealmakers

Austria

Biotechnology

AcquisitionPrivateMajorityCross Border

target

Erber Group

bidder

Royal Dsm

£880m

dealmakers

India

Pharmaceuticals

Private EquityPrivateMinorityAcquisitionCross Border

target

Piramal Pharma

bidder

The Carlyle Group

£397m

dealmakers

Italy

Pharmaceuticals

MajorityAcquisitionPrivatePrivate EquityCross BorderMbo

target

Genetic Group

bidder

Cvc Capital Partners

£254m

dealmakers

Germany

Pharmaceuticals

PrivateCross BorderAcquisitionPrivate EquityMajority

target

NEURAXPHARM

bidder

Permira Advisers

£1,468m

dealmakers

Switzerland

Biotechnology

Cross BorderAcquisitionMajorityPrivate

target

Om Pharma

bidder

Optimus Holding

£369m

dealmakers

Belgium

Pharmaceuticals

MajorityAcquisitionPrivateCross BorderPrivate Equity

target

Ceres Pharma

bidder

Naxicap Partners

value n/a

dealmakers

Germany

Pharmaceuticals

AcquisitionPrivateMajorityMergerCross BorderPrivate Equity

target

Pharmazell Group

bidder

NOVASEP

value n/a

dealmakers

Belgium

Pharmaceuticals

MajorityCross BorderPrivateAcquisitionPrivate Equity

target

SYLPHAR

bidder

Karo Pharma

£242m

dealmakers

India

Pharmaceuticals

MajorityCross BorderPrivateAcquisition

target

Synergia Life Sciences

bidder

Novozymes As

£112m

dealmakers

Spain

Pharmaceuticals

Private EquityPrivateMajorityAcquisitionCross Border

target

SUANFARMA

bidder

Archimed

value n/a

dealmakers

United Kingdom

Pharmaceuticals

Cross BorderMajorityPrivate EquityPrivateAcquisition

target

THERAMEX

bidder

Pai Partners

£1,062m

dealmakers

Switzerland

Pharmaceuticals

AcquisitionMajorityCross BorderPrivate

target

Refarmed Group

bidder

Dksh Holding

value n/a

dealmakers

Spain

Pharmaceuticals

AcquisitionCross BorderPrivate EquityMajorityPrivate

target

INKE

bidder

Keensight Capital

£211m

dealmakers

United States

Biotechnology

PrivateAcquisitionCross BorderMajority

target

Coherus Biosciences (cimerli Business)

bidder

SANDOZ

£133m

dealmakers

Ireland

Pharmaceuticals

PrivateMinorityAcquisitionPrivate EquityCross Border

target

Chanelle Pharma

bidder

Exponent Private Equity

value n/a

dealmakers

ChileBelgium

Software

MajorityCross BorderAcquisitionPrivate

target

Neuralis

bidder

Gedeon Richter

£147m

dealmakers

Denmark

Pharmaceuticals

Private EquityMinorityCross BorderAcquisitionPrivate

target

Orifarm Group

bidder

The Carlyle Group

value n/a

dealmakers